TITLE

Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial

AUTHOR(S)
Dhainaut, Jean-François; Laterre, Pierre-François; Janes, Jonathan M.; Bernard, Gordon R.; Artigas, Antonio; Bakker, Jan; Riess, Hanno; Basson, Bruce R.; Charpentier, Julien; Utterback, Barbara G.; Vincent, Jean-Louis; Dhainaut, Jean-François; Laterre, Pierre-François; Recombinant Human Activated Protein C Worldwide Evaluation in Sepsis (PROWESS) Study Group
PUB. DATE
June 2003
SOURCE
Intensive Care Medicine;Jun2003, Vol. 29 Issue 6, p894
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Objective: Based on the results of the PROWESS trial the European Agency for the Evaluation of Medicinal Products has recently approved drotrecogin alfa (activated) for treatment of adult patients with severe sepsis and multiple-organ failure. We report study's data on efficacy and safety in patients with multiple-organ dysfunction.Design and Setting: Randomized, double-blind, placebo-controlled, multicenter trial in 164 medical centers.Patients: 1271 patients (75.2% of the intention-to-treat population, n=1690) with multiple-organ dysfunction at study entry.Interventions: Drotrecogin alfa (activated) n=634, 24 micro g/kg per hour for 96 h or placebo ( n=637).Results: Observed 28-day mortality was significantly lower with drug treatment than with placebo (26.5%vs. 33.9%), cardiovascular and respiratory organ dysfunction resolved more rapidly over the first 7 days, and serious bleeding events were more frequent (2.4% vs. 1.3%).Conclusions: Treatment with drotrecogin alfa (activated) significantly reduced 28-day mortality and more quickly resolved cardiovascular and respiratory organ dysfunction. The difference in serious bleeding event rates may be clinically significant; however, the overall benefit-risk profile appears favorable.
ACCESSION #
16629449

 

Related Articles

  • Alkaline phosphatase for treatment of sepsisinduced acute kidney injury: a prospective randomized double-blind placebo-controlled trial.  // Critical Care;2012, Vol. 16 Issue 1, pR14 

    The article presents a study on alkaline phosphatase for treatment of sepsisinduced acute kidney injury. In the study, thirty-six adult patients with severe sepsis or septic shock according to Systemic Inflammatory Response Syndrome criteria and renal injury defined according to the AKI Network...

  • A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock.  // Critical Care;2012, Vol. 16 Issue 1, pR31 

    The article presents a study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock. In the study, seventy patients received AZD9773 or placebo. Mean baseline APACHE score...

  • An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS): protocol for a randomized controlled trial. Orme, Robert M. ĽE.; Perkins, Gavin D.; McAuley, Daniel F.; Liu, Kathleen D.; Mason, Alexina J.; Morelli, Andrea; Singer, Mervyn; Ashby, Deborah; Gordon, Anthony C. // Trials;2014, Vol. 15 Issue 1, p1 

    Background Organ dysfunction consequent to infection ('severe sepsis') is the leading cause of admission to an intensive care unit (ICU). In both animal models and early clinical studies the calcium channel sensitizer levosimendan has been demonstrated to have potentially beneficial effects on...

  • EMERGING THERAPIES IN SEVERE SEPSIS. Finney, S. J.; Evans, T. W. // Thorax;Oct2002 Supplement 2, Vol. 57, pii8 

    Context Activation of the coagulation system and depletion of endogenous anticoagulants are frequently found in patients with severe sepsis and septic shock. Diffuse microthrombus formation may induce organ dysfunction and lead to excess mortality in septic shock Antithrombin III may provide...

  • The use of placebo in a trial of rectal artesunate as initial treatment for severe malaria patients en route to referral clinics: ethical issues. Kitua, Andrew; Folb, Peter; Warsame, Marian; Binka, Fred; Faiz, Abul; Ribeiro, Isabela; Peto, Tom; Gyapong, John; Yunus, Emran Bin; Rahman, Ridwan; Baiden, Frank; Clerk, Christine; Mrango, Zakayo; Makasi, Charles; Kimbute, Omari; Hossain, Amir; Samad, Rasheda; Gomes, Melba // Journal of Medical Ethics;Feb2010, Vol. 36 Issue 2, p12 

    Placebo-controlled trials are controversial when individuals might be denied existing beneficial medical interventions. In the case of malaria, most patients die in rural villages without healthcare facilities. An artesunate suppository that can be given by minimally skilled persons might be of...

  • Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. Annane, Djillali; Bellissant, Eric; Bollaert, Pierre Edouard; Briegel, Josef; Keh, Didier; Kupfer, Yizhak // BMJ: British Medical Journal (International Edition);8/28/2004, Vol. 329 Issue 7464, p480 

    Objective To assess the effects of corticosteroids on mortality in patients with severe sepsis and septic shock. Data sources Randomised and quasi-randomised trials of corticosteroids versus placebo (or supportive treatment alone) retrieved from the Cochrane infectious diseases group's trials...

  • A systematic approach to hemoptysis. Lenner, Roberta; Almenoff, Peter L. // Patient Care;9/30/1999, Vol. 33 Issue 15, p49 

    Focuses on the possible causes of respiratory hemoptysis, its diagnosis and the appropriate management of the condition. Signs and symptoms; Diagnostic evaluation; Indications for bronchoscopy; Advantages of high-resolution computed tomography used in diagnostic evaluation; Treatment;...

  • Unexplained hemoptysis. Kalamkar, Shailesh; Joshi, J. M. // Lung India;Apr-Jun2012, Vol. 29 Issue 2, p187 

    A quiz regarding an unexplained hemoptysis with the presence of rhonchus in the respiratory system of a 37-year-old man is presented.

  • Amoxicillin of minimal benefit for purulent rhinorrhea. Schellhase, Kenneth G.; Fay, David L. // Journal of Family Practice;Aug2002, Vol. 51 Issue 8, p672 

    The article presents a study which examined the effect of amoxicillin in patients with upper respiratory tract infections involving purulent rhinorrhea. Treatment success rate on day 10 and the duration of general illness, pain and purulent rhinorrhea were the primary outcomes. Incidence of side...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics